Welcome to ALNARA
Alnara Pharmaceuticals, Inc. is dedicated to developing novel protein therapeutics for the treatment of metabolic diseases. The company's innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream. Based in Cambridge, Massachusetts, Alnara is backed by top-tier venture investors, including Frazier Healthcare Ventures, Third Rock Ventures and Bessemer Venture Partners.
Spotlight
Alnara Pharmaceuticals announced today the promotion of Robert Gallotto to chief business officer. This appointment reflects Alnara’s growing operations as the company prepares to submit a new drug application (NDA) and commercialize liprotamase, a novel, oral, porcine-free pancreatic enzyme replacement therapy (PERT) that has already completed a Phase 3 efficacy trial. For more information click here.
LATEST NEWS
6.2.09 - Alnara Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
